Quick Answer
INTEGRATED BIOPHARMA INC reported Stockholders Equity of $20.32 million for the year ending 2025.
- INTEGRATED BIOPHARMA INC showed an increase of +5.6% in Stockholders Equity from 2024 to 2025.
- This data is from INTEGRATED BIOPHARMA INC's annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2011: -$8.10 million | Q1 2012: -$8.83 million | Q3 2012: -$11.36 million | Q4 2012: -$10.54 million | Q1 2013: -$11.07 million | Q3 2013: -$9.99 million | Q1 2014: -$10.04 million | Q3 2014: -$9.75 million | Q4 2014: -$9.20 million | Q1 2015: -$9.31 million | Q3 2015: -$9.07 million | Q4 2015: -$9.12 million | Q1 2016: -$9.08 million | Q3 2016: -$7.67 million | Q4 2016: -$7.73 million | Q1 2017: -$7.48 million | Q3 2017: -$6.10 million | Q4 2017: -$6.45 million | Q1 2018: -$6.06 million | Q3 2018: $196.0 thousand | Q4 2018: $466.0 thousand | Q1 2019: $1.39 million | Q3 2019: $2.22 million | Q4 2019: $3.19 million | Q1 2020: $4.14 million | Q3 2020: $7.12 million | Q4 2020: $8.43 million | Q1 2021: $9.75 million | Q3 2021: $14.89 million | Q4 2021: $16.07 million | Q1 2022: $16.98 million | Q3 2022: $18.62 million | Q4 2022: $18.65 million | Q1 2023: $18.7 thousand | Q3 2023: $18.89 million | Q4 2023: $18.57 million | Q1 2024: $18.91 million | Q2 2024: $19.24 million | Q3 2024: $18.55 million | Q4 2024: $19.73 million | Q1 2025: $20.38 million | Q2 2025: $20.32 million | Q3 2025: $20.49 million | Q4 2025: $19.77 million.
- Over the full 16 years of available data (2010 to 2025), INTEGRATED BIOPHARMA INC's Stockholders Equity has grown by 456.7%.
- Historical annual values: Fiscal year 2025: $20.32 million | Fiscal year 2024: $19.24 million | Fiscal year 2023: $18.86 million | Fiscal year 2022: $18.58 million | Fiscal year 2021: $14.33 million | Fiscal year 2020: $6.07 million | Fiscal year 2019: $1.89 million | Fiscal year 2018: -$5.24 million | Fiscal year 2017: -$5.93 million | Fiscal year 2016: -$8.33 million | Fiscal year 2015: -$9.32 million | Fiscal year 2014: -$10.16 million | Fiscal year 2013: -$10.29 million | Fiscal year 2012: -$10.38 million | Fiscal year 2011: -$7.70 million | Fiscal year 2010: -$5.70 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: